In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147

Jingli Hao1,2, Michele C. Madigan3, Aparajita Khatri4, Carl A. Power5, Tzong-Tyng Hung4,5, Julia Beretov1,2,6, Lei Chang1,2, Weiwei Xiao1,2, Paul J. Cozzi1,7, Peter H. Graham1,2, John H. Kearsley1,2, Yong Li1,2*

1 St George Clinical School, University of New South Wales (UNSW), Kensington, New South Wales, Australia, 2 Cancer Care Centre, St George Hospital, Kogarah, New South Wales, Australia, 3 School of Optometry and Vision Science, University of New South Wales (UNSW), Kensington, New South Wales, Australia, 4 Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, 4 Prince of Wales Clinical School, University of New South Wales (UNSW), Kensington, New South Wales, Australia, 5 Biological Resources Imaging Laboratory, University of New South Wales (UNSW), Kensington, New South Wales, Australia, 6 Department of Anatomical Pathology, St George Hospital, Kogarah, New South Wales, Australia, 7 Department of Surgery, St George Hospital, Kogarah, New South Wales, Australia

Abstract

CD44 and CD147 are associated with cancer metastasis and progression. Our purpose in the study was to investigate the effects of down-regulation of CD44 or CD147 on the metastatic ability of prostate cancer (CaP) cells, their docetaxel (DTX) responsiveness and potential mechanisms involved in vitro and in vivo. CD44 and CD147 were knocked down (KD) in PC-3M-luc CaP cells using short hairpin RNA (shRNA). Expression of CD44, CD147, MRPI2 (multi-drug resistance protein-2) and MCT4 (monocarboxylate transporter-4) was evaluated using immunofluorescence and Western blotting. The DTX dose-response and proliferation was measured by MTT and colony assays, respectively. The invasive potential was assessed using a matrigel chamber assay. Signal transduction proteins in PI3K/Akt and MAPK/Erk pathways were assessed by Western blotting. An in vivo subcutaneous (s.c.) xenograft model was established to assess CaP tumorigenicity, lymph node metastases and DTX response. Our results indicated that KD of CD44 or CD147 decreased MCT4 and MRPI2 expression, reduced CaP proliferation and invasive potential and enhanced DTX sensitivity; and KD of CD44 or CD147 down-regulated p-Akt and p-Erk, the main signal modulators associated with cell growth and survival. In vivo, CD44 or CD147 KD PC-3M-luc xenografts displayed suppressed tumor growth with increased DTX responsiveness compared to control xenografts. Both CD44 and CD147 enhance metastatic capacity and chemoresistance of CaP cells, potentially mediated by activation of the PI3K and MAPK pathways. Selective targeting of CD44/CD147 alone or combined with DTX may limit CaP metastasis and increase chemosensitivity, with promise for future CaP treatment.

Introduction

Prostate cancer (CaP) is the most commonly diagnosed and the second leading cause of death from cancer in males in the USA [1]. While initially responsive to androgen deprivation therapy (ADT), most patients suffer from cancer recurrence after 12 months, and CaP at this stage is no longer curable [2]. The progression of CaP to an advanced stage is characterized by the dissemination of malignant cancer cells and small cell clusters through lymphatics and blood vessels. Although several genetic and epigenetic changes are reported in CaP progression, the cellular mechanisms involved in progression of localized CaP to metastatic disease remain undefined.

Chemotherapy is traditionally used for palliation of symptoms associated with advanced CaP. Two recent docetaxel (DTX)-based clinical studies have for the first time shown the potential benefits of chemotherapy to prolong the survival time and life quality of CaP patients [3,4]. DTX is currently the most effective chemotherapeutic drug for metastatic CaP [3–6]. However, the drug-resistant nature of CaP still challenges the effectiveness of such therapies. Clearly, multidrug resistance and metastatic disease remain the main causes of treatment failure and mortality in CaP patients. Thus, it is of significant value to investigate the mechanisms and pathways of CaP metastasis and drug resistance, identify useful therapeutic targets to improve current therapeutic modalities.

CD44 is a multifunctional protein involved in cell adhesion, migration, drug resistance, signal transmission, migration and apoptosis [7,8]. The CD44 gene contains 20 exons alternatively spliced to give many isoforms or variants (CD44v), some of which form the invariant extracellular domain of standard CD44...
CD147 is a primary receptor for hyaluronan (HA), a major component of the extracellular matrix (ECM) and critical for cell signaling and cell-ECM interactions in cancer. CD44-HA binding stimulates downstream effects on cytoskeleton proteins implicated in tumor cell migration, as well as stimulating multidrug resistance protein 1 (MDR1) expression and drug resistance [9]. CD44s is present on the membrane of most vertebrate cells [7]. The expression of certain CD44 variants is reported to be closely associated with tumor progression, and this varies depending on tumor type studied [10]. Intriguing studies have implicated HA/CD44 interactions in epithelial mesenchymal-transition (EMT), “stemness” and cancer [11,12]. The interaction between HA and CD44 has been shown to trigger pathways related to tumor growth and survival [13,14]. However, the role of CD44s and CD44v in CaP development and progression is different, with studies showing both tumor-inhibiting (CD44s) and tumor-promoting (CD44v) effects [15–17]. The involvement of CD44 and its variants in CaP progression and metastases warrants further investigation.

CD147 (extracellular matrix metalloproteinase inducer protein-EMMPRIN) is a multifunctional glycoprotein that can modify tumor microenvironment by activating proteinases, inducing angiogenic factors in both tumor and stromal cells, and regulating growth and survival of anchorage-independent tumor cells (micrometastases) as well as multidrug resistance [18]. Transcriptome analysis and comparative genomic hybridization of individual tumor cells isolated from bone marrow of patients with CaP showed that CD147 is the most frequently expressed protein in primary tumors and micrometastases [19]. Moreover, increased CD147 expression is associated with increased risks including prostate specific antigen (PSA) failure, metastasis, and reduced overall survival in human CaP [20]. We recently showed that the high levels of CD147 expression correlate with CaP progression and are associated with the expression of MMPs (matrix metalloproteinases) in tumor as well as stromal cells [21]. These results suggest that CD147 could be a useful therapeutic target for CaP therapy. However, the role of CD147 in CaP metastasis and drug resistance remains unclear.

In the current study, we hypothesized that (1) CD44 and CD147 expression correlate with the metastatic capacity and chemoresistance of CaP and may co-operate to influence CaP progression and (2) down-regulation of CD44 or CD147 expression could have therapeutic potential in limiting CaP metastasis and enhancing CaP chemotherapeutic sensitivity. We demonstrate in the following sections that CD44 and CD147 confer properties significant for CaP metastasis and chemoresistance in vitro and in vivo, and are useful therapeutic targets for future CaP therapy.

Materials and Methods

Antibodies

Antibodies were obtained from different sources. The detailed information and conditions for all antibodies are listed in Table 1.

Cell line and cell culture

The androgen-non-responsive PC-3M-luc-C6 (PC-3M-luc) CaP cell line was obtained from Xenogen Corp, USA. All tissue culture reagents were supplied by Invitrogen Australia Pty Ltd (Melbourne, VIC, Australia), unless otherwise stated. PC-3M-luc cells were cultured in RPMI-1640 supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), 50 U/mL of penicillin, and 50 U/mL of streptomycin. PC-3M-luc-shRNA (scrambled shRNA control), PC-3M-luc-CD44-knockdown (KD), PC-3M-luc-CD147-KD cells were grown in the same medium supplemented with additional 1 μg/mL puromycin for screening. All cell lines were maintained in a humidified incubator at 37°C and 5% CO2.

Short hairpin RNA (shRNA) transfection for CD44/CD147

PC-3M-luc cells with shRNA-mediated KD of CD44 (s and v)/CD147 or a scrambled sequence control for off-target effects (PC-3M-luc-scr) were generated using a previously published method with modification [22]. Five MISSION® lentiviral transduction particles encoding for shRNAs against CD44 or CD147 and MISSION® non-target shRNA control transduction particles were used (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, Australia) (Table S1). Briefly, 2 × 106 PC-3M-luc cells were cultured in 24 well plates and transduced with all five clones of lentiviral particles or the same amount of non-target shRNA control transduction particles following the manufacturer’s protocol (multiplicity of infection = 2, viral transducing units/cell). The transduced clones were selected in puromycin-containing cell culture medium (0.5 μg/mL) (Invitrogen Australia Pty Ltd, Melbourne, VIC, Australia), propagated and finally transferred to the 25 cm2 cell culture flasks and maintained in medium containing 1.0 μg/mL puromycin for the following experiments.

Immunofluorescence confocal microscopy analysis of PC-3M-luc and PC-3M-luc-KD cell lines

Immunofluorescence staining was performed as previously described [23]. Briefly, cells grown on glass coverslips were fixed, rinsed and incubated with various primary antibodies overnight (o/n) at 4°C: mouse anti-human CD44 monoclonal antibody (MAb) (1:200 dilution), CD147 polyclonal antibody (PAb) (1:100 dilution), MRP2 MAb (1:50 dilution), rabbit anti-human MCT1 PAb (1:200 dilution) or MCT4 PAb (1:400 dilution). After rinsing in TBS, cells were incubated for 45 minutes in Alexa Fluor-488 goat anti-mouse or Alexa Fluor-488 goat anti-rabbit IgG (1000 dilutions) at room temperature (RT). Propidium iodide (PI) (0.2 mg/mL) was used to stain the nuclei. Negative controls were treated identically but incubated with either mouse or rabbit isotype control. Immunofluorescence was visualized using an FV300/FV500 Olympus laser scanning confocal microscope (Olympus, Tokyo, Japan).

Western blotting analysis

Protein expression levels were determined by Western blotting analysis as described [24]. Briefly, whole cell lysates were separated by NuPAGE Novex 4–12% Bis-Tris gel electrophoresis and then transferred to polyvinylidene difluoride membrane. After blocking of non-specific sites with 5% skim milk, the membrane was incubated with specific antibodies at appropriate concentrations (Table 1), followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (goat anti-mouse or goat anti-rabbit appropriate for the host species of primary antibody) (1:5000 dilution). Immunoreactive bands were detected using enhanced chemiluminescence (ECL) substrate (Pierce Chemical Co, Rockford, USA), and imaged using the ImageQuant LAS4000 system (GE Health care, USA). To confirm equal loading of protein lysates, membranes were stripped (Restore Western Blot Stripping Buffer, Pierce) and re-probed using mouse anti-β-tubulin MAB (1:10000 dilution), then processed as above. Images were processed in Adobe Photoshop.

Co-immunoprecipitation (IP) assay

Cell lysate containing 200 μg whole cell lysates from PC-3M-luc cells, was incubated with 2 μg of anti-CD44 or anti-CD147 antibodies (Abs) or normal serum (Ig control) o/n at 4°C. Immune complexes were isolated by precipitation using protein A/G
PLUS-agarose (Santa Cruz Biotechnology, Inc, USA) for 8 h at 4°C. Beads were washed 4 times at 1000 g and were suspended in 20 μL of NuPAGE LDS sample buffer (Invitrogen Australia Pty Ltd, Australia), then heated at 100°C for 5 minutes. Extracts were then immunoblotted with CD44 and CD147 primary antibodies, followed by incubation with HRP-conjugated secondary antibodies and detected using ECL substrate. Image analysis was as described above (Western blotting).

**MTT assay for DTX response**

MTT assays were performed as described previously [24]. Briefly, cells were seeded in 96-well plates and treated with a range of concentrations (0.001–1000 nM) of DTX diluted in 100% ethanol, and a vehicle control. After 72 h incubation, the medium was replaced with fresh medium containing 0.5 mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. After 4 h, the supernatants were removed and the resulting MTT formazan solubilized in DMSO and measured spectrophotometrically at 562 nm on a BIO-TEK microplate reader (Bio-Rad, Hercules, CA, USA). Results represent the OD ratio of DTX-treated and vehicle-treated cells. The growth inhibition curve was generated using the GraphPad Prism 4 Program (GraphPad, San Diego, CA, USA). Absolute IC50 values were calculated using the intersection of the 50% normalised drug response and the growth inhibition curves for each cell line, to find the x axis values for IC50 DTX concentration (nM).

**Colony forming assays**

PC-3M-luc and PC-3M-luc-KD cells were used for colony forming assays as described previously with minor modifications.

---

**Table 1. Antibodies used for western blot (WB), immunofluorescence (IF), immunohistochemistry (IHC) staining and immunoprecipitation (IP).**

| Antibody | Source | Type | Dilution | Incubation time (min) | Temperature | Application |
|----------|--------|------|----------|----------------------|-------------|-------------|
| Mouse anti-human CD44 (DF1485) | Santa Cruz Biotechnology | MAb | 1:200 (WB, IF) | O/N | 4°C | WB, IF, IP |
| Rabbit anti-human CD147 | Invitrogen | PAb | 1:400 (WB) | O/N | 4°C | WB, IF, IP |
| Rabbit anti-human MCT1 | Santa Cruz Biotechnology | PAb | 1:400 (WB, IF) | O/N | 4°C | WB, IF |
| Rabbit anti-human MCT4 | Santa Cruz Biotechnology | PAb | 1:400 (WB, IF) | O/N | 4°C | WB, IF |
| Mouse anti-human MRP2 | Enzo Life Sciences | PAb | 1:100 (WB) 1:50 (IF) | O/N | 4°C | WB, IF |
| Rabbit anti-human phospho-Merlin (Ser518) antibody | Cell Signaling Technology | PAb | 1:1000 (WB) | O/N | 4°C | WB |
| Rabbit anti-human Akt1/2/3 (Thr173) antibody | Santa Cruz Biotechnology | PAb | 1:200 | O/N | 4°C | WB |
| Rabbit anti-human Phospho-Akt | Cell Signaling Technology | PAb | 1:500 (WB) | O/N | 4°C | WB |
| Rabbit anti-human p44/42 MAPK (Erk1/2) antibody | Cell Signaling Technology | PAb | 1:500 (WB) | O/N | 4°C | WB |
| Rabbit anti-human phospho-Erk1 (pT202/pY204/Erk2 (pT185/pY187) | Epitomics, Inc. | MAb | 1:500 (WB) | O/N | 4°C | WB |
| Mouse anti-human β-tubulin | Sigma | MAb | 1:10000 (WB) | O/N | 4°C | WB |
| Mouse anti-human β-tubulin | Sigma | MAb | 1:10000 (WB) | O/N | 4°C | WB |
| Mouse anti-human β-tubulin | Sigma | MAb | 1:10000 (WB) | O/N | 4°C | WB |
| Mouse anti-human IgG1-negative control | Dako | IgG1 | 1:1000 (IF) | O/N | 4°C | IF |
| Mouse anti-human IgG1-negative control | Dako | IgG1 | 1:1000 (IF) | O/N | 4°C | IF |
| Goat anti-mouse Alexa Fluor® 488 Dye Conjugate | Invitrogen | IgG | 1:1000 (IF) | 45 | RT | IF |
| Goat anti-rabbit Alexa Fluor® 488 Dye Conjugate | Invitrogen | IgG | 1:1000 (IF) | 45 | RT | IF |
| Goat anti-mouse IgG-HRP | Santa Cruz Biotechnology | PAb | 1:150 (IHC) | 45 | RT | IHC |
| Goat anti-mouse IgG-HRP | Santa Cruz Biotechnology | PAb | 1:150 (IHC) | 45 | RT | IHC |
| Goat anti-mouse IgG-HRP | Santa Cruz Biotechnology | PAb | 1:150 (IHC) | 45 | RT | IHC |

**Notes:** MAb: monoclonal antibody; O/N: overnight; PAb: polyclonal antibody; RT: room temperature.

doi:10.1371/journal.pone.0040716.t001
Matrigel invasion assay
Invasive ability of CaP cell lines was determined using commercial matrigel and control transwell chambers (BD Biosciences, NSW, Australia). Briefly, 2×104 PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD CaP cells in 500 µL serum-free medium were added to each transwell insert and 750 µL complete medium was added to the outer well to provide chemoattractant and prevent dehydration. Cells were incubated at 37 °C in 5% CO₂ for 24 h and then stained with a Diff-Quik staining kit (Allegiance Healthcare Corp, McGraw Park, Illinois, USA). Excess dye was washed away with tap water and the number of stained cells that invaded through matrigel or control inserts was counted in five high power fields (hpf) by light microscopy (Leica microscope, Nussloch, Germany). Invasive potential was calculated as follows: % Invasion = [(Mean cells invading through matrigel insert membrane)/ (Mean cells migrating through control insert membrane)] × 100%. Cell invasion rates were plotted, with mean and SD (n = 3).

Subcutaneous (s.c.) xenograft animal model
Male, 6–8 weeks old Balb/c nude mice (Animal Resources Centre, Western Australia) were housed under specific pathogen-free conditions in facilities approved by the University of New South Wales (UNSW) Animal Care and Ethics Committee (ACEC) and manipulations were performed in laminar flow cabinets. The ACEC specifically approved this study (approval ID is 10/121A). Mice were kept at least 1 week before experimental manipulation. All mice remained healthy and active during the experiment. As described previously [26], cultured PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD or PC-3M-luc-CD147-KD CaP cells (1.5 x 10⁶/injection) in 100 µL DPBS were implanted subcutaneously in the right rear flank region of mice (n = 10 mice/ per group). Tumor progression was documented weekly by measurements using calipers, and tumor volumes were calculated as follows: length × width × height × 0.52 (in millimeters) [27] for up to 8 weeks. Upon sacrifice, primary tumors and local regional lymph nodes were removed for histological examination.

DTX response in CaP s.c. animal model
After establishing s.c. models with CaP cell lines, when average tumor size reached 30±2 cm³ in each subgroup (n = 10/ subgroup), 5 mice (n = 5) were treated with 25 mg/kg DTX continuously for 3 weeks by i.p. injection, and 5 mice (n = 5) were treated with vehicle control (saline). Tumor growth was calculated by measurements using calipers as published [27].

Mouse tissues and histology
All tissues were either formalin fixed or snap frozen. Hematoxylin and eosin (H&E)-stained sections were reviewed to assess tumor structure. Tumor xenografts and local regional lymph nodes were collected at the end of experiments and processed for histology, immunohistochemistry and TUNEL assay. Five-micron frozen sections of fresh tumor samples were used for CD31 and CD44 immunostaining.

Immunohistochemistry
Standard immunoperoxidase procedures were used to visualize CD147, Ki-67, and caspase-3 (active) as previously published [28]. Briefly, paraffin sections were dewaxed and rehydrated, then incubated with primary antibodies (Abs) anti-CD147 (1:200), Ki-67 (1:1000 dilution) and caspase-3 (active) (1:100 dilution), respectively o/n at 4 °C. Slides were then incubated with swine anti-goat, mouse, rabbit biotinylated IgG second antibody (1:150 dilution) for 45 minutes at RT and with streptavidin/HRP solution (1:300 dilution) for 30 minutes at RT. Sections were finally developed with 3,3′-diaminobenzidine (DAB) substrate solution (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, Australia), then counterstained with hematoxylin; positive cells appeared brown. Control slides were treated in an identical manner, and using isotype Abs or omitting primary antibody as a negative control.

CD44 and CD31 immunostaining on frozen sections were performed as previously published [28]. Sections were incubated with mouse anti-human CD44 (1:200 dilution) or rat anti-mouse CD31 MAb (1:100 dilution) o/n at 4 °C. Sections were incubated with rabbit anti-mouse/rat biotinylated IgG (1:200 dilution) for 45 minutes at RT, and then with conjugated streptavidin/HRP (1:200 dilution) for another 30 minutes. Sections were developed by using DAB solution (Sigma-Aldrich, Pty Ltd, Castle Hills, NSW, Australia), and counterstained with hematoxylin. For negative controls, sections were stained with the isotype MAb or with omitting primary antibodies.

TUNEL assay for apoptotic cells in vivo
Apoptosis was assessed on tumor xenograft tissues using the TUNEL method with the TdT-fragEL in situ apoptotic detection kit (Calbiochem, San Diego, CA, USA) according to the manufacturer’s instructions. The specificity of TUNEL reactivity was confirmed with appropriate negative (TdT omitted from the labeling mix) and positive (treated HL-60 slides provided by the company) controls. Slides were examined using a Leica light microscope (Nussloch, Germany).

Assessment of immunostaining
Staining intensity (0–3) was assessed using light microscopy (Leica, Germany) and a x40 objective. The criteria used for assessment were as previously reported [29], where: 0 (negative, <25%); 1+ (weak, 25–50%); 2+ (moderate, 50–70%); 3+ (strong, >75%) of the tumor cells stained. Evaluation of tissue staining was done, independently, by three experienced observers (JH, JB and YL). All specimens were scored blind and an average of grades was taken.

Statistical analysis
All numerical data were expressed as the average of the values obtained, and the standard deviation (SD) was calculated. Data from different groups were compared using the two-tail student’s t test. All P values were 2-sided. The statistical analysis of immunostaining intensity in animal xenografts was performed as described in a recent publication [28]. One-way ANOVA, followed by the Dunnett’s post hoc test was performed to determine the significance of differences between the growth curves in s.c. model for tumor volume changes. P<0.05 was considered significant. All numerical statistical analyses were...
performed using the GraphPad Prism 4.00 package (GraphPad, San Diego CA).

**Results**

Expression of CD44, CD147, MCT4 and MRP2 in CD44 or CD147-KD and control cell lines

PC-3M-luc and PC-3M-luc-scr CaP cell lines showed strong positive staining for CD44, CD147, MCT4 and MRP2 (Fig. 1A). Following CD44 knock down, the reduction in CD44 expression was also associated with a concomitant reduction in the levels of expression of CD147, MCT4 and MRP2 (Fig. 1A). Similarly, after knocking down CD147, the levels of CD147 expression were reduced and a concomitant reduction in the levels of expression of CD44, MCT4 and MRP2 was also seen (Fig. 1A). No detectable staining was seen in the cells incubated with isotype controls (data not shown). The immunofluorescence staining results in different CaP cell lines are summarized in Table 2. The immunofluorescence results for the expression of CD44, CD147, MCT4 and MRP2 in CaP cell lines were further confirmed by western blotting (Fig. 1B). PC-3M-luc cell lysates were also immunoprecipitated with either anti-CD44 antibody, anti-CD147 antibody or normal serum (Ig), and immunoblotted with CD44 and CD147 Abs (Fig. 1C). Both CD44 (90 KDa) and CD147 (~50 KDa) bands were detected in anti-CD44 and anti-CD147 antibody IP lysates respectively, but not in the Ig precipitated lysate.

Knock down of CD44 or CD147 sensitizes monolayer CaP cells to DTX treatment *in vitro*

KD (PC-3M-luc-KD-CD44 and PC-3M-luc-KD-CD147) and control (PC-3M-luc and PC-3M-luc-scr) CaP cell lines with different levels of CD44 and CD147 expression responded differently to DTX treatment. The IC50 values (the dose for obtaining 50% cell killing) strongly correlated with the levels of CD44 and CD147 expression (Fig. 2A). Accordingly, PC-3M-luc and PC-3M-luc-scr control cells (high levels of CD44 and CD147) were the least sensitive (IC50: 118 and 104 nM, respectively), while PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD cells (low levels of CD44 and CD147) were very sensitive to DTX treatment.

**Table 2.** Immunostaining for CD44, CD147, MCT4 and MRP2 in KD and control prostate cancer (CaP) cell lines.

| Cell Line       | CD44 | CD147 | MCT4 | MRP2 |
|-----------------|------|-------|------|------|
| PC-3M-luc       | 2–3  | 2–3   | 3    | 1–2  |
| PC-3M-luc-scr   | 2–3  | 2–3   | 3    | 1–2  |
| PC-3M-luc-CD44-KD | 0–1 | 1–2   | 1–2  | 0–1  |
| PC-3M-luc-CD147-KD | 1–2 | 0–1   | 0    | 1    |

Notes: Immunofluorescence staining: 0 = negative; 1 = weak; 2 = moderate; 3 = strong.

KD: knock down; scr: scrambled shRNA control.

**Figure 1.** The expression of CD44 and CD147 in PC-3M-luc cells and the effects of reducing CD44 or CD147 on each other and/or MRP2 and MCT4 in CaP cell lines. Representative confocal images of CD44, CD147, MCT4 and MRP2 (green) immunofluorescence after knocking down CD44 or CD147 (A). Nuclei are stained with PI (red). Magnification: all images ×400. Representative western blot is shown to confirm the immunofluorescence staining (B). β-tubulin was used as a loading control. scr: scrambled shRNA control. PC-3M-luc cell lysates immunoprecipitated with anti-CD44, anti-CD147 antibody, and normal serum (Ig) followed by immunoblotting with either CD44 or CD147 antibodies (C). IB: immunoblotting; IP: Immunoprecipitation.

doi:10.1371/journal.pone.0040716.g001
IC$_{50}$: 7 and 19 nM, respectively). Significant differences ($P<0.05$) in the IC$_{50}$ was observed between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD cells and PC-3M-luc/PC-3M-luc-scr cells.

Knock down of CD44 or CD147 reduces clonogenic ability and sensitizes CaP colonies to DTX treatment

To investigate whether KD of CD44 and CD147 affect the clonogenicity of either alone or combined with DTX treatment, we assessed KD and control CaP cells in culture. The number of colonies was significantly decreased either with vehicle control or with DTX treatment in PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD cell lines compared to controls. Significant differences ($P<0.05$) in the average number of colonies was observed between DTX treated cells and VC treated cells in PC-3M-luc/PC-3M-luc-scr cell lines ($P<0.05$) compared to controls.

Knock down of CD44 or CD147 reduces clonogenic ability and sensitizes CaP colonies to DTX treatment
treated PC-3M-luc-CD44-KD/CD147-KD cells and VC treated PC-3M-luc/PC-3M-luc-scr cells. Representative images are shown in Fig. 2B. The DTX response in PC-3M-luc-CD44 or CD147-KD cell lines was greater than for PC-3M-luc and PC-3M-luc-scr cell lines (Fig. 2C). The clonogeneity (average DTX-treated colonies/average vehicle control-treated colonies) was 89%, 84%, 56% and 74% for PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD, and PC-3M-luc-CD147-KD cell lines, respectively.

Knock down of CD44 or CD147 reduces CaP cell invasion
After knocking down CD44 or CD147, cell invasion was significantly reduced for both PC-3M-luc-CD44-KD (P<0.001) and PC-3M-luc-CD147-KD cells (P<0.01) compared with PC-3M-luc and PC-3M-luc-scr control cells (Fig. 2D). A relatively greater reduction in invasion ability was found in PC-3M-luc-CD44-KD cells than in PC-3M-luc-CD147-KD cells (Fig. 2D). The percentage invasion for PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD cells was 70%, 62%, 22%, and 47% respectively (Fig. 2D). Representative images for each cell line are shown in Fig. 2E.

PI3K/Akt and MAPK/Erk signaling pathways are related to the expression of CD44 and CD147 in CaP cells
After knocking down CD44 or CD147, we found that the expression of p-Akt and p-Erk were both downregulated in PC-3M-luc-CD44-KD or CD147-KD cells compared to PC-3M-luc and PC-3M-luc-scr control cells, with more significant reduction in PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD cells; there was no obvious change in t-Akt and t-Erk expression in all CaP cell lines (Fig. 2F).

Knock down of CD44 or CD147 affects tumorigenicity, lymph node metastases and DTX sensitivity in a s.c. xenograft model
As shown in the tumor growth graphs in Fig. 3A, compared with scr control, the weekly measurements of CD44 and CD147 KD xenografts, treated either with vehicle control (VC) or DTX (25 mg/kg), showed a significantly reduced tumor growth rate in both VC (P<0.05) and DTX-treated groups (P<0.05) (on the left and middle panels). There were no significant differences in the tumor growth rate of PC-3M-luc wild-type and PC-3M-luc-scr xenografts in either VC or DTX treated groups (P>0.05). In VC-treated xenografts, a slightly stronger regression of tumor growth was seen in CD44 KD xenografts compared with CD147 KD xenografts, while no obvious difference was found between growth of CD44 KD and CD147 KD tumors (P>0.05). In the DTX-treated xenografts, the tumor xenografts from the four CaP cell lines had smaller tumor volumes compared to corresponding VC-treated xenografts at all time points (P<0.05). Slightly more tumor regression is seen in DTX-treated CD44-KD xenografts but no significant difference is found between CD44-KD and CD147-KD growth curves (P>0.05). In addition, we compared the ratio of tumor volumes between DTX and VC treated xenografts (DTX/VC) (Fig. 3A, right panel). The ratio of CD44-KD and CD147-KD tumor volumes (DTX/VC) decreased faster in response to DTX or VC treatment, suggesting that the KD of either CD44 or CD147 can induce suppression of tumor development, compared to the scr and wild-type xenografts.

We also evaluated tumor weight changes in each group at completion of the experiments (8 weeks post cell inoculation) (Fig. 3B). We found no significant difference in weight between the parental and scramble-transfected cell lines, showing that the cells’ in vivo characteristics was not altered by the transfection process (Fig. 3B and C). At this time point, CD44-KD and CD147-KD xenografts both showed significantly reduced tumor weights compared to control groups (789±192 mg for PC-3M-luc-CD44-KD and 892±236 mg for PC-3M-luc-CD147-KD versus 1369±117 mg for PC-3M-luc and 1376±250 mg for PC-3M-luc-scr, respectively). This represented 58% and 63% weight reductions in KD-treated versus scr-control groups (P<0.05), respectively (Fig. 3B and C). In addition, we observed an obvious decrease in overall body weight in the DTX-treated mice compared to the untreated control mice (P<0.05, unpublished data). There was also an obvious delay in weight gain after DTX treatment in all mice (unpublished data).

All mice from control groups without DTX treatment developed regional lymph node metastases; no lymph node metastases were seen in CD44- or CD147-KD control mice treated with DTX (Fig. S1). Tumor volumes of mice with KD xenografts were less than control groups, and tumor volumes of DTX-treated mice were less than VC-treated mice. Typical tumor sizes including lymph node metastases are shown in Fig. 3C.

Tumor xenografts histology following CD44 or CD147-KD with or without DTX treatment
To compare the histology of each group, tumors from control mice (PC-3M-luc- and PC-3M-luc-scr-xenografts) and KD mice (PC-3M-luc-CD44-KD- and PC-3M-luc-CD147-KD-xenografts) treated with VC and DTX were harvested at the end of the experiments, paraffin embedded, sectioned and stained with H&E. With light microscopy (Fig. 4), PC-3M-luc and PC-3M-luc-scr tumor xenografts in VC treated groups consisted of tightly packed cells. Loosely packed or dispersed tumor cells associated with areas of cell death were apparent in both PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD xenografts (Fig. 4A). In DTX-treated groups, the tumors were less densely packed with necrotic and apoptotic regions in all groups. This was greater in PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD xenografts, compared to PC-3M-luc or PC-3M-luc-scr tumors (Fig. 4B).

Assessment of tumor microvascular density in CD44 or CD147-KD tumor xenografts with/without DTX treatment
To assess the effect of CD44 or CD147-KD on vascular density in different xenografts, frozen sections of tumors were stained with CD31 Ab. Representative images for CD31 expression in VC-treated mice (Fig. 4C and D) were shown. Microvascular density (MVD) (number of CD31 positive cells/ hpfx) was high in PC-3M-luc and PC-3M-luc-scr xenografts treated with VC; this was decreased in VC treated PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD xenografts; with the greatest reduction in DTX treated in PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD xenografts (Fig. 4C and D).

The numbers of CD31+ vessels/ per area in PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD groups were 16–20/ hpfx, 9–13/ hpfx, 6–10/ hpfx, 5–8/ hpfx, respectively in VC-treated mice. The numbers of CD31+ vessels/ per area in PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD groups were 14–19/ hpfx, 9–12/ hpfx, 6–8/ hpfx, 2–5/ hpfx, respectively in DTX-treated mice. The CD31 immunostaining results are summarized in Table 3. The difference in staining intensity for CD31 between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc/PC-3M-luc-scr cell lines was significant (P<0.05). PC-3M-luc-CD147-KD xenografts had less CD31 expression in DTX-treated mice.
CD44 and CD147 expression in tumor xenografts after knock down of CD44 or CD147

A

At the end of experiments, expression of CD44 and CD147 was examined for the VC-treated xenografts from PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD cells with CD44 and CD147 Abs. Our results indicated high levels of CD44 expression in PC-3M-luc and PC-3M-luc-scr xenografts (95–100%, +++); intermediate levels of CD44 in CD147 KD xenografts (40–50%, ++); low levels of CD44 in CD44 KD xenografts (30%–40%, +) (Fig. 4E, Table 3). A significant difference in staining intensity for CD44 expression was found between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc/PC-3M-luc-scr cell lines (P<0.05). High levels of CD147 were observed in PC-3M-luc (80–90%, ++++) and PC-3M-luc-scr xenografts (70–80%, +++); low levels of CD147 in CD44 KD xenografts (20–30%, +); very low levels of CD147 in CD147 KD xenografts (~20%, +) (Fig. 4F, Table 3). The difference in staining intensity for CD147 expression found between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc/PC-3M-luc-scr cell lines was significant (P<0.05). These results suggest that CD44 and CD147-KD can significantly reduce CD44/CD147 expression and affect each other in PC-3M-luc xenografts.

Cell proliferation, cell death and apoptosis in tumor xenografts after CD44 or CD147-KD with or without DTX treatment

B

To investigate whether knock down of CD44/CD147 in CaP cells affect proliferative potential either alone or in response to DTX in vivo, tumor sections from nude mice were assessed for Ki-67 expression. At the end of experiments (8 weeks), high numbers of Ki-67+ tumor cells were seen in PC-3M-luc (80–90%) and PC-3M-luc-scr (70–80%) xenografts; modest Ki-67+ tumor cells in PC-3M-luc-CD44-KD (60–70%) and PC-3M-luc-CD147-KD (60–70%) xenografts with VC-treatment suggesting that the KD has limited effects on the proliferation of the CaP cells. The difference in staining intensity for Ki-67+ cells between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc/PC-3M-luc-scr cell lines was significant (P<0.05). DTX treatment successfully reduced the number of proliferative cells in all groups, and but with small differences between the control and the KD groups (Table 3). Representative images are shown in Fig. 5A and B.
To investigate whether apoptosis may be involved in the targeted lesions of tumor xenografts, TUNEL assay was used. Representative results are shown in Fig. 5C and D. At the end of experiments, TUNEL-positive tumor cells from PC-3M-luc-CD44-KD (28–35/ hpf) and PC-3M-luc-CD147-KD (30–36/ hpf) xenografts in DTX-treated groups displayed typical apoptotic cell morphology with nuclear chromatin condensation and fragmentation. Tumor cells from PC-3M-luc (11–15/ hpf) and
Table 3. The intensity of immunohistochemical staining of CD44, CD147, Ki-67, Caspase-3 (active), TUNEL in tumor xenografts from PC-3M-luc, PC-3M-luc-scr, PC-3M-luc-CD44-KD and PC-3M-luc-CD147-KD with DTX and/or vehicle treatment.

|                     | PC-3M-luc | PC-3M-luc-scr | PC-3M-luc-CD44-KD | PC-3M-luc-CD147-KD |
|---------------------|-----------|---------------|-------------------|-------------------|
|                     | VC        | DTX           | VC                | DTX              |
| CD44                | 95–100%   | N/A           | 95–100%           | N/A              |
|                     | +++       | +             | +++               | +                |
| CD147               | 80–90%    | 70–80%        | 20–30%            | ~20%             |
|                     | +++       | +             | +                 | ++               |
| CD31                | 16–20/hpf | 14–19/hpf     | 9–13/hpf          | 12–17/hpf        |
|                     | +++       | +++           | +++               | ++               |
| Ki-67               | 70–80%    | 60–70%        | 60–80%            | 50%              |
|                     | +++       | +++           | +++               | ++               |
| Caspase-3 (a)       | 0–5/hpf   | 8–12/hpf      | 1–7/hpf           | 30–35/hpf        |
|                     | –         | +             | +                 | 20–25/hpf        |
| TUNEL               | 0–5/hpf   | 11–15/hpf     | 0–6/hpf           | 28–35/hpf        |
|                     | –         | ++            | +                 | ++               |

Notes: a: active; DTX: docetaxel; hpf: high power fields; KD: knocking down; N/A: not available; scr: scrambled shRNA control; VC: vehicle control.

caspase-3 (active) xenografts after DTX treatment; high level of in PC-3M-luc-scr (15–19/ hpf) xenografts with VC-treated groups showed few apoptotic cells; almost no apoptotic cells were found in PC-3M-luc and PC-3M-luc-scr cell lines was significant (P<0.05). We observed very high levels of caspase-3 (active) cells in PC-3M-luc-scr xenografts with DTX treatment; high level of caspase-3 (active) cells in PC-3M-luc (8–12/ hpf) and PC-3M-luc-scr (8–13/ hpf) xenografts with DTX treatment; medium level of caspase-3 (active) cells in PC-3M-luc-CD44-KD (7–10/ hpf) and PC-3M-luc-CD147-KD (12–17/ hpf) with VC treatment; only few caspase-3 (active) cells in PC-3M-luc (0–5/ hpf) and PC-3M-luc-scr (1–7/ hpf) with VC treatment (Table 3). The difference in staining intensity for caspase-3 (active) between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD xenograft model.

PC-3M-luc-scr (15–19/ hpf) xenografts with DTX-treatment showed fewer apoptotic cells while tumors from PC-3M-luc-CD44-KD (17–21/ hpf) and PC-3M-luc-CD147-KD (12–18/ hpf) xenografts with VC-treated groups showed few apoptotic cells; almost no apoptotic cells were found in PC-3M-luc and PC-3M-luc-scr xenografts for VC-treated mice (Fig. 5C and D, Table 3). The significant difference in staining intensity for TUNEL-positive areas was seen between PC-3M-luc-CD44-KD/PC-3M-luc-CD147-KD and PC-3M-luc-scr xenografts with VC-treated mice (Fig. 5E and F, Table 3). We recently reported that CD44 and CD147 co-localize on both primary and metastatic CaP cells, and that over-expression of CD44v3-10 and CD147 is associated with CaP progression; Furthermore, we found a clear inverse relationship between DTX sensitivity and CD44v3-10/CD44v7 expression in CaP cell lines [21,24]. In the present study we further investigated the roles of CD44 or CD147 in CaP metastasis and DTX responsiveness using in vivo CD44 or CD147-KD CaP cell lines and an in vivo s.c. xenograft model.

Previous reports have shown that CD44 and CD147 are close partners in various cancers [30–32]. CD147 stimulates production of HA [33], an extracellular polysaccharide that promotes tumor chemoresistance through interactions with the cell surface receptor CD44 [34–36]. CD147, through interactions with HA receptors (CD44) [36] and membrane-bound transporters [37], facilitates tumor cell chemoresistance. In addition, disruption of HA interactions with its cognate receptors interferes with CD147-mediated drug resistance [36] in part through disruption of protein complexes containing CD147 [30,31]. In the present study, we found that knocking down either CD44 or CD147 affects the expression of the other protein to a lesser extent, as well as impacting on the expression of drug resistance protein (MRP2) and transporter protein (MCT4) in CaP cells. These data suggest that CD44 and CD147 are co-regulated and associated with MRP2 and MCT4 in CaP cells, and may play an important role in CaP metastasis and chemoresistance, although this remains to be confirmed in further studies.

The association of CD44 and CD147 with MCT transporter proteins has been documented for different cancers [30,31,37–39]. Metastatic cancer cells increase glucose consumption and metabolism via glycolysis, producing large quantities of lactate. Up-regulation of glycolysis and adaptation to acidosis are key events in the transition from in situ to invasive cancer [40]. The rapid transport of lactate by MCTs is of critical importance for almost all cells, especially tumor cells with elevated levels of glycolysis resulting in a decrease in extracellular pH. MCT4 and CD147 overexpression have been reported to be associated with poor prognosis in CaP [41]. Rudrabhatla et al reported that MCT4 is an important efflux pump for lactate and that the accumulation of lactate in the microenvironment may stimulate HA production and contribute to an acquired malignancy in melanoma cells [42]. MRP2 is one of 48 human ATP-binding cassette (ABC) transporters, also called ABCG2/the canalicular multiple organic anion transporter (cMOAT), and plays a role in the occurrence of the MDR phenotype in cancer cells [43]. An association with MCT4 or MRP2 is often an attribute of an aggressive phenotype and drug resistance in cancers [24,44,45]. CD147 silencing has been reported to inhibit MCT1/MCT4 and reduce the malignant

Discussion

We recently reported that CD44 and CD147 co-localize on both primary and metastatic CaP cells, and that over-expression of CD44v3-10 and CD147 is associated with CaP progression; Furthermore, we found a clear inverse relationship between DTX sensitivity and CD44v3-10/CD44v7 expression in CaP cell lines [21,24]. In the present study we further investigated the roles of CD44 or CD147 in CaP metastasis and DTX responsiveness using in vivo CD44 or CD147-KD CaP cell lines and an in vivo s.c. xenograft model.
potential of pancreatic cancer cells in vivo and in vitro [46]. The mechanisms underlying how CD44 and CD147 may regulate or influence MCT4 and MRP2 are not well defined. However, modifications of MCT4 and MRP2 can influence tumor growth and sensitivity to chemotherapy, and are a useful approach for cancer treatment [47,48]. In the current study, we found that reducing CD44 or CD147 expression related to the concurrent reduction of MCT4 and MRP2 could increase the sensitivity of...
CaP cells to DTX treatment. This suggests that the effect of the DTX-related response after CD44 or CD147-KD in CaP cells may be functionally related to MCT4 and MRP2 expression and particular signaling pathways. In addition, CD44-KD clearly enhanced the greater sensitivity to DTX compared to CD147 KD cells, suggesting a possible stronger inhibition of survival pathways.

Colonies formation assays provide a more appropriate measure of the long-term effects of potential therapeutic agents, assessing the ability of cells to retain proliferative potential after treatment, a characteristic that clinically facilitates tumor recurrences in patients. Our clonogenic assays indicated that downregulated expression of CD44 or CD147 suppressed the survival potential of CaP cells in the presence of either vehicle or DTX treatment. The sensitivity to DTX treatment was also higher in CD44 or CD147-KD cells compared to control cells, suggesting that CD44 and CD147 play an important role in CaP growth and DTX resistance. Wang et al. reported that inhibition of CD41 expression reduces tumor cell invasion in PC-3 CaP cells via RNA interference [49]. Zhu et al. also found that CD147 regulates cell adhesion, invasion, and cytoskeleton reorganization in PC-3 CaP cells using a shRNA approach [50]. In this study, we also found reduced in vitro invasion for CD44 or CD147-KD cells compared to control cells; this was greater in CD44-KD cells indicating that both CD44 and CD147 affect CaP invasion and that CD44 plays a more important role in invasion than CD147 does. The matrigel invasion assay mimics the ECM microenvironment by providing growth factors and creating a matrix scaffold for tumor cells to invade through. One possible mechanism for the reduced invasion observed in this study could be reduced levels of MMPs (for example, MMP-9) as observed with gelatin zymography for CaP cells with reduced CD44 or CD147 expression (unpublished observation).

PI3K/Akt and MAPK/Erk signaling pathways are related to CaP invasion [51,52]. PI3K activation can induce chemoresistance in CaP cells through the up-regulation of MRP1 [53]. Activated forms of Akt can also increase the drug resistance of advanced CaP, and the PI3K/PTEN/Akt pathway appears to be more prominently involved in CaP drug resistance than the Raf/MEK/Erk pathway [54]. One recent study reported that PTEN/PI3K/Akt pathways are critical for maintaining a CaP stem-like cell (CD44+/CD133+) phenotype and that targeting PI3K signaling may be beneficial in CaP treatment by eliminating CaP stem-like cells [55]. We hypothesized that CD44 and CD147 might be involved in PI3K/Akt or MAPK/Erk signaling pathways in CaP metastasis and drug resistance. In the current study, we found that CD44 or CD147-KD could reduce both p-Akt and p-Erk levels in CaP cells. A more obvious reduction of p-Akt and p-Erk was seen in CD44-KD cells, suggesting that both PI3K/Akt and MAPK/Erk signaling pathways are involved in CD44/CD147-mediated CaP metastasis and drug resistance, and that CD44 plays a prominent role in this regulation compared to CD147. These findings are consistent with the colony assay, cell invasion and DTX responsiveness results. The role of CD44 and CD147 in the regulation of these two signaling pathways will be investigated in future studies.

To further validate our in vitro findings, we also studied an s.c. xenograft animal model. Metastases derived from s.c. human CaP PC-3 xenografts line have been reported [56] and we have previously described the development of CaP lymph node metastases in 100% of nude mice injected with PC-3 cells after 8 weeks [26]. The PC-3M-luc xenograft model we developed has 100% tumor take, with 100% local regional lymph node metastases post 8 weeks cell inoculation. This provides an appropriate model to mimic clinical CaP metastasis. Our findings indicated that CD44 or CD147-KD with VC treatment strongly regressed tumor progression for at least 8 weeks. Tumor volumes at the end of experiment in the CD44 or CD147-KD mice decreased by 37% and 35% respectively compared with the scr-controls. After 3 weeks continuous treatment with DTX, obvious tumor growth regression was found in CD44- or CD147-KD mice compared with the controls. The sensitivity rate to DTX treatment was higher in CD44- or CD147-KD cells compared to control cells. These results further confirmed the in vitro colony assay observations. CD44- or CD147-KD cell lines treated with VC or DTX can also completely prevent lymph node metastases for at least 8 weeks, during which period all control mice treated with VC developed lymph node metastases. These results suggest that CD44- or CD147-KD inhibit the growth of PC-3M-luc tumors, increase DTX response and prevent local regional lymphode metastases. Furthermore, combining CD44- or CD147-KD with DTX could have advantages over a single treatment approach and can greatly reduce tumor growth and reduce tumor burden.

In the current study, we used shRNA lentiviral transfection for the CD44- or CD147-KD cell lines to stably reduce CD44 and CD147 expression and ensure continued downregulation during the in vivo tumorigenecity study. Our results indicate that in vitro CD44 or CD147-KD remained downregulated in the in vivo biological system for 8 weeks post-cell inoculation, and that the data from the current model system are reliable. We also found that compared to control cell lines, CD44- and CD147-KD affected the expression of each other in the animal xenografts, consistent with the in vitro findings from the same cell lines (Fig. 1).

In CD44- or CD147-KD xenografts treated with VC or DTX, we found a comparatively dispersed tumor structure, with evidence of scattered targeted areas. Angiogenesis plays a critical role in tumor progression, providing adequate nutritional and oxygen supply essential for tumor proliferation and metastasis, and promoting tumor recovery following cytotoxicity [57]. In fact, the angiogenic potential of a tumor is directly correlated with poor prognosis [58]. In the present study, we found a profoundly reduced MVD (CD31 expression/hpf) in the CD44 or CD147-KD xenografts, especially the CD147 KD tumors, suggesting that CD44 and CD147 are related to CaP angiogenesis and that targeting CD44 and CD147 can inhibit CaP angiogenesis. CD147 is reported to affect angiogenesis mainly via three mechanisms: a) Inducing proteinases which cleave VEGF from the ECM; b) Stimulating the production of tumor-derived VEGF; and c) Increasing VEGFR2 expression on the endothelial cells [59]. However, the exact mechanism by which CD147 affects angiogenesis in CaP remains to be determined. As for how CD44 can influence CaP angiogenesis, one possibility is that CD44 regulated MMP production cleaves ECM-bound VEGF, similar to CD47. We have found reduced MMP-9 production in CD44-KD cells (unpublished data). Another possibility is that CD147-KD induced inhibition of angiogenesis leads to a secondary CD44-associated effect of tumor vasculature.

DTX is now considered the preferred chemotherapeutic agent for castrate-resistant prostate cancer (CRPC) and bone metastasis [60]. The most widely described mechanism by which DTX achieves this effect is through its activity as a mitotic spindle poison, disrupting microtubule dynamics and inducing G2/M cell cycle arrest, a downstream effect thought to be related to the phosphorylation of Bcl-2 [61]. As expected, DTX could inhibit tumor growth compared with VC treatment (P<0.05, see Fig. 3), with larger targeted areas and reduced MVD in DTX-treated mice. In a recent study, we also demonstrated that DTX could inhibit epithelial ovarian cancer (EOC) growth in an i.p. OVCAAR-5 model through inhibition of tumor angiogenesis [28]. In the
current study, CD44 or CD147-KD xenografts treated with DTX, showed significant targeted areas with tumor islands and obviously reduced MVD, suggesting that DTX may have a similar antiangiogenic function as seen in the EOC model [28]. The exact mechanisms by which the combination of CD44 or CD147-KD and DTX affect angiogenesis and vascular regression will be investigated in future studies.

As described above, CD44 or CD147-KD could effectively inhibit tumor growth and reduce tumor volume and MVD combined with DTX treatment. While the mechanisms for this remain unclear, we conducted preliminary studies to determine whether apoptosis was involved, including TUNEL and caspase-3 activation assays; caspase-3 activation is critical for the proteolytic cleavage of many key proteins during apoptosis [62]. We observed reduced cell proliferation in CD44 or CD147-KD and DTX-treated xenografts, which was further reduced in CD44/CD147-KD xenografts combined with DTX treatment. The number of apoptotic cells (TUNEL-positive) and caspase-3 (active) positive cells in PC-3M-luc-CD44/CD147-KD tumors also increased, consistent with tumor regression being related to reduced cancer cell proliferation and apoptosis.

In summary, we have demonstrated for the first time that both CD44 and CD147 are involved in CaP proliferation, invasion and chemoresistance, possibly mediated through activation of both PI3K/Akt and MAPK/Erk pathways in vitro. Furthermore, reducing either CD44 or CD147 expression effectively reduced CaP tumor growth, enhanced the response to DTX, reduced angiogenesis and induced apoptosis in vivo. Consequently, combination targeting of CD44 and CD147 with DTX provides a potent therapeutic approach for advanced, recurrent, CRPC.

Supporting Information

Figure S1 Lymph node metastases in different CaP groups after treatments. Representative images demonstrating lymph node metastases (LNMs) in histology (H&E staining) 8 weeks post cell inoculation in different CaP groups with different treatments. LNM was found in PC-3M-luc xenograft mice (A) and PC-3M-luc-scr xenograft mice (B) but not in PC-3M-luc-CD44-KD xenograft mice (C) and PC-3M-luc-CD147 xenograft mice (D). The arrows indicate PC-3M-luc metastatic cancer cells in local regional lymph nodes. Magnification ×100, 200, 400 in all images. KD: knock down; scr: scrambled shRNA control. (TIFF)

Table S1 Sequences of CD44 and CD147 shRNA lentiviral transduction particles. (DOC)

Acknowledgments

We thank the Xenogen Corp, USA for providing PC-3M-luc cell line.

Author Contributions

Conceived and designed the experiments: JLH MGM AK CAP PJG JHK YL. Performed the experiments: JLH TTH JB LC WWX. Analyzed the data: JHL CAP TTH PHG JHK YL. Contributed reagents/materials/analysis tools: CAP. Wrote the paper: JHL YL.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
2. Chang SS, Kheel AS (2009) The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103: 8–17.
3. Tanooki IF, de Wit R, Berry WR, Horti J, Fluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 350: 1532–1537.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520.
5. Calabro F, Sternberg CN (2007) Current indications for chemotherapy in prostate cancer patients. Eur Urol 51: 17–26.
6. Petrylak DP (2005) Future directions in the treatment of androgen-independent prostate cancer. Urology 65: 8–12.
7. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 18: 280–287.
8. Ponta H, Sherman L, Herlihy PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33–45.
9. Bourguignon LY, P娆rollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog. Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635–17651.
10. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y (2010) CD44/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Drug Targets 11: 287–306.
11. Brown RL, Reinke LM, Damerson MS, Perez D, Chodosh LA, et al. (2011) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121: 4067–4074.
12. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, et al. (2009) Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26: 433–446.
13. Bai Y, Liu YJ, Wang H, Xu Y, Stamakovic I, et al. (2007) Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressive activity of melanin. Oncogene 26: 836–850.
14. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, et al. (2011) Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 71: 4083–4095.
15. Gao AC, Louis W, Sherman JP, Isaacs JT (1998) Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 58: 2530–2532.
16. Omar-Opyene AL, Qiu J, Shah GV, Iczkowski KA (2004) Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Mcuc10. Lab Invest 84: 894–907.
17. Yang K, Tang Y, Habermanh GK, Iczkowski KA (2010) Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer 10: 16.
18. Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emrinin (basigin, CD147), in tumour progression. Thorub Haematol 93: 199–204.
19. Klein CA, Seiff S, Petat-Dutter K, Offner S, Geijt JB, et al. (2002) Combined transcriptionite and genome analysis of single micrometastatic cells. Nat Biotechnol 20: 387–392.
20. Zhong WD, Liang YX, Lin SX, Li L, He HC, et al. (2011) Expression of CD147 is associated with prostate cancer progression. Int J Cancer 130: 300–308.
21. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, et al. (2008) The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57: 1367–1379.
22. Qin XF, An DS, Chen IS, Baltimore D (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100: 183–188.
23. Chen H, Hao J, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432–440.
24. Hao J, Chen H, Madigan MC, Cozzi PJ, Berstov J, et al. (2010) Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103: 1008–1018.
25. Wang L, Chen H, Liu F, Madigan MC, Power CA, et al. (2011) Monoclonal antibody targeting MUC1 increases sensitivity to docetaxel as a novel strategy in treating epithelial ovarian cancer. Cancer Lett 300: 122–133.
26. Li Y, Kizzi SM, Ramson M, Allen BJ (2002) 2138b-PAE conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 86: 1197–1203.
27. Gleave M, Huie JT, Gao CA, von Eschenbach AC, Chung LW (1991) Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753–3761.
28. Wang L, Chen H, Pourgholami MH, Berstov J, Hao J, et al. (2011) Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Alter Lymphatic Functioning lymph node metastases (LNM) in histology (H&E staining) 8 weeks post cell inoculation in different CaP groups with different treatments. LNM was found in PC-3M-luc xenograft mice (A) and PC-3M-luc-scr xenograft mice (B) but not in PC-3M-luc-CD44-KD xenograft mice (C) and PC-3M-luc-CD147 xenograft mice (D). The arrows indicate PC-3M-luc metastatic cancer cells in local regional lymph nodes. Magnification ×100, 200, 400 in all images. KD: knock down; scr: scrambled shRNA control. (TIFF)
30. Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, et al. (2009) Hyaluronan, CD44, and emmprin regulate lactate eflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 69: 1293–1301.

31. Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, et al. (2009) Inhibition of Functional Hyaluronan-CD44 Interactions in CD133+ positive primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res 15: 7593–7601.

32. Toole BP, Slomiany MG (2008) Hyaluronan, CD44 and Emmpin: partners in cancer cell chemoresistance. Drug Resist Update 11: 110–121.

33. Marieb EA, Zoltan-Jones A, Li R, Mira S, Ghatak S, et al. (2004) Emmpin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64: 1229–1232.

34. Gilg AG, Tye SY, Tolliver LB, Wheeler WG, Visconti RP, et al. (2008) Targeting hyaluronan interactions in malignant gliomas and their drug-resistant malignant progenitors. Clin Cancer Res 14: 1304–1313.

35. Mira S, Ghatak S, Toole BP (2003) Regulation of multidrug resistance protein 2 (MRP2) expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinoside 3-kinase, and ErbB2. J Biol Chem 280: 20310–20315.

36. Mira S, Ghatak S, Toole BP, Slomiany MG (2003) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278: 25285–25290.

37. Wang WJ, Li QQ, Xu JD, Cao XX, Li HX, et al. (2008) Interaction between CD147 and Pglycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 54: 291–301.

38. Milleti-Gonzalez KE, Chen S, Muthukumaran N, Saglinbeni GN, Wu X, et al. (2005) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65: 6660–6667.

39. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Krane DA, et al. (2009) Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 69: 4992–4998.

40. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.

41. Petteng-Gomes N, Vizcaíno JR, Miranda-Gonzales V, Pinheiro C, Silva J, et al. (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is related closely to the prognosis of patients with ovarian carcinoma. Obstet Gynecol 118: 1378–1387.

42. Grozeva D, Kim S, Sabalowski CM, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268–273.

43. Wang L, Wu G, Yu L, Yuan J, Fang F, et al. (2006) Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5: 608–614.

44. Chakravarty A, Zolling-Knoll A, Desnoyers S, Zeng Z, et al. (1995) CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801–809.

45. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, et al. (2011) Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 102: 1007–1013.

46. Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279: 149–157.

47. Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279: 149–157.

48. Wang L, Yu G, Yu L, Yuan J, Fang F, et al. (2006) Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5: 608–614.

49. Zhou H, Zhao J, Zhu B, Collazo J, Gal J, et al. (2012) EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate 72: 72–81.

50. Shukla S, Macleanin GT, Hartman DJ, Fu P, Resnick MI, et al. (2007) Activation of PI3K/Akt pathway promotes prostate cancer cell invasion. Int J Cancer 12: 1424–1432.

51. Slomiany MG, Dai L, Tolliver LB, Wheeler WG, Visconti RP, et al. (2008) Targeting hyaluronan interactions in malignant gliomas and their drug-resistant malignant progenitors. Clin Cancer Res 14: 1304–1313.

52. Mira S, Ghatak S, Toole BP, Slomiany MG (2003) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278: 25285–25290.

53. Wang WJ, Li QQ, Xu JD, Cao XX, Li HX, et al. (2008) Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 54: 291–301.

54. Milleti-Gonzalez KE, Chen S, Muthukumaran N, Saglinbeni GN, Wu X, et al. (2005) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65: 6660–6667.

55. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Krane DA, et al. (2009) Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 69: 4992–4998.

56. Chakravarty A, Zolling-Knoll A, Desnoyers S, Zeng Z, et al. (1995) CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801–809.